Literature DB >> 3518930

Serial circulating immune complex values and development of metastatic disease in breast cancer and malignant melanoma patients.

Z Ronai, J Shaham, J Stein, D Sulitzeanu.   

Abstract

A polyethylene glycol precipitation technique was used to determine the levels of circulating immune complexes (CIC) in breast cancer and melanoma patients. All patients in the study had undergone surgery and were free of distant metastatic disease. CIC were measured at two to four time intervals, of 3 to 6 months each, over an average follow-up period of 13.5 months (range 7-20 months). In both groups of patients, metastatic disease developed with a higher frequency in patients who had undetectable CIC levels throughout the follow-up period or had become negative at the time metastases were discovered.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3518930     DOI: 10.1007/bf00205720

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  12 in total

1.  Rapid isolation of antigens from cells with a staphylococcal protein A-antibody adsorbent: parameters of the interaction of antibody-antigen complexes with protein A.

Authors:  S W Kessler
Journal:  J Immunol       Date:  1975-12       Impact factor: 5.422

2.  Microassay using radioiodinated protein A from Staphylococcus aureus for antibodies bound to cell surface antigens of adherent tumor cells.

Authors:  P M Zeltzer; R C Seeger
Journal:  J Immunol Methods       Date:  1977       Impact factor: 2.303

Review 3.  Human cancer-associated antigens: present status and implications for immunodiagnosis.

Authors:  D Sulitzeanu
Journal:  Adv Cancer Res       Date:  1985       Impact factor: 6.242

4.  Clinical significance of circulating immune complexes in patients with metastatic breast cancer.

Authors:  G Krieger; A Kehl; H E Wander; A M Salo; H F Rauschecker; G A Nagel
Journal:  Int J Cancer       Date:  1983-02-15       Impact factor: 7.396

5.  Antigens in immune complexes from patients with breast cancer. Identification of autoantigens in immune complexes isolated from breast cancer effusions.

Authors:  Z Gilead; A Hatzubai; D Sulitzeanu
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

6.  Circulating immune complexes and tumor cell cytotoxins as prognostic indicators in malignant melanoma: a prospective study of 53 patients.

Authors:  R D Rossen; M M Crane; A C Morgan; E H Giannini; B C Giovanella; J S Stehlin; J J Twomey; E M Hersh
Journal:  Cancer Res       Date:  1983-01       Impact factor: 12.701

7.  Report on international comparative evaluation of possible value of assays for immune complexes for diagnosis of human breast cancer.

Authors:  R B Herberman; M Bordes; P H Lambert; H S Luthra; R A Robins; P Sizaret; A Theofilopoulos
Journal:  Int J Cancer       Date:  1981-05-15       Impact factor: 7.396

8.  Limitations of immune complex measurements in colorectal disease.

Authors:  J Hobbiss; K M Cooper; M Moore; E Gowland; P F Schofield
Journal:  Br J Surg       Date:  1983-08       Impact factor: 6.939

9.  A simple, rapid and sensitive assay for immune complexes using a Staphylococcus aureus immunoadsorbent.

Authors:  T Barkas
Journal:  J Clin Lab Immunol       Date:  1981-01

10.  Circulating immune complexes in patients with colorectal cancer.

Authors:  G Steele; S Lahey; M Rodrick; D Ross; J Deasy; N Zamcheck; R Osteen; R Wilson
Journal:  Am J Surg       Date:  1983-04       Impact factor: 2.565

View more
  1 in total

1.  Prognostic value of serial determinations of circulating immune complex levels in malignant melanoma.

Authors:  A Bukh; A Møller-Larsen; M T Aguado; F Møller-Larsen; N P Møller
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.